-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A new pharmaceutical company has been born!Haizheng Pfizer, named Hanyu Pharmaceuticals
On June 29, Zhejiang Haizheng Pharmaceuticals issued a "Announcement on the Name Of the Holding Subsidiary".
announced that its controlling subsidiary, Haizheng Pfizer Pharmaceuticals, has been approved by the Fuyang District Market Supervision Authority of Hangzhou City, the name changed to "Hanyu Pharmaceutical Co., Ltd." The relevant industrial and commercial registration change procedures have been completed, and obtained a new "business license."
source close to Haizheng Pharmaceuticals told SaibaiLan that its employees yesterday (28) have received a formal name change notice, reimbursement bills, product information and other materials have been updated. The notice requires that the words "Pfizer" and LOGO will no longer be used in mail, PPT and various documents as of that date.""new" pharmaceutical company, annual revenue of 3.9 billion
since then, the new peach "Hanyu Pharmaceuticals" replaced the old character "Hai Zheng Pfizer";
haizheng and Pfizer's marriage officially ended on November 11, 2017, Haizheng Pharmaceuticals issued a "suggestive announcement on the change of equity of the controlling subsidiary Haizheng Pfizer Co., Ltd." Pfizer will no longer directly or indirectly hold any equity interest in Haizheng Pfizer after transferring its 49% stake in Haizheng Pfizer to GaoZheng Capital.
is understood to be the largest private equity fund in Asia, with a focus on long-term structured value investments. Pfizer and Haizheng formed a joint venture on September 13, 2012, ending a five-year marriage.
's 2017 annual report shows that Haizheng Pfizer's current independent marketing network covers 31 provinces (municipalities and autonomous regions) and more than 4,500 hospitals. Revenue for 2017 was $3.97 billion, with net profit attributable to the parent company of $480 million.joint venture change, in early August official Xuan
on the name change of the enterprise, yesterday the author called Haizheng Pharmaceuticals, the other side of the announcement of information other than no comment. In fact, on June 1-2, at the 2nd MayoClinic China Hospital Management Summit in Shanghai, the materials on display were already the name of Hanyu Pharmaceuticals.
people close to Haizheng Pharmaceuticals said the company's name change has been in full play, around the beginning of August will hold a press conference to officially put Hanyu Pharmaceuticals in public, including the replacement of packaging products, management composition, business operations planning and so on.
's feelings about the replacement of the joint venture, the source did not disclose. (Seber Blue)